Related Experiment Videos
Chronic obstructive pulmonary disease: emerging therapies.
1Department of Pulmonary Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA. douglas_w_hay@sbphrd.com
Current Opinion in Chemical Biology
|August 26, 2000
Summary
New phosphodiesterase 4 inhibitors, like Ariflo, show significant clinical efficacy for chronic obstructive pulmonary disease (COPD). This promising therapeutic class represents a major advance in pulmonary medicine for treating COPD patients.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) has high prevalence and mortality rates.
- Research into COPD pathophysiology and therapeutics is still developing.
- Novel molecular targets are under investigation for COPD treatment.
Purpose of the Study:
- To investigate the efficacy of novel therapeutics for chronic obstructive pulmonary disease.
- To highlight the potential of phosphodiesterase 4 inhibitors as a new treatment class.
Main Methods:
- Clinical trials evaluating novel compounds.
- Focus on Ariflo (SB 207499), a phosphodiesterase 4 inhibitor in Phase III development.
Main Results:
- Ariflo demonstrated significant clinical efficacy in COPD patients.
- Phosphodiesterase 4 inhibitors are a promising new class of compounds.
Conclusions:
- Phosphodiesterase 4 inhibitors, exemplified by Ariflo, represent a significant advancement in pulmonary medicine.
- These inhibitors offer potential for improved COPD management.